Skip to content

Vivek Ramaswamy

Republican · OH

Official website

Vivek Ramaswamy is a biotechnology entrepreneur and author who sought the Republican presidential nomination in 2024. His Ohio campaign emphasizes economic growth, education policy, and reducing regulation and state spending.

Where Vivek Ramaswamy stands, based on their records

Supports

Government Efficiency (1 record)

Opposes

Corporate Accountability (2 records)

Track record

Track record — Government Efficiency

Government Efficiency · 1 support
  • Helped develop the planned Department of Government Efficiency during the presidential transition, then left the initiative before it began operating under the new administration.

    January 20, 2025Supports Government Efficiency

    Source: apnews.com

Track record — Corporate Accountability

Corporate Accountability · 2 oppose
  • Ramaswamy co-founded Strive Asset Management, which organized investor advocacy against corporate ESG mandates and quota-based management policies.

    August 17, 2023Opposes Corporate Accountability

    Source: strive.com

  • As Strive Asset Management's executive chairman, sent a shareholder letter pressing Disney to focus on financial performance rather than political objectives.

    September 20, 2022Opposes Corporate Accountability

    Source: strive.com

Track record — General

General · 17 records
  • His campaign took credit for a TV ad in which Amy Acton's estranged mother said Acton lies about her past. Gov. Mike DeWine called the ad "deeply, deeply troubling" and urged the campaign to take it down.

    October 20, 2026

    Source: statenews.org

  • Received the endorsement of the Ohio State Medical Association's political action committee, the doctors' group, over Dr. Amy Acton.

    September 17, 2026

    Source: signalohio.org

  • Received the Ohio Fraternal Order of Police's endorsement for governor; it is the state's largest police union.

    July 23, 2026

    Source: signalohio.org

  • Received Ohio Gov. Mike DeWine's endorsement for governor.

    January 7, 2026

    Source: spectrumnews1.com

  • Received the Ohio Conference of Teamsters' endorsement for governor; the union conference represented more than 50,000 workers in the state.

    September 19, 2025

    Source: semafor.com

  • Received the Ohio Chamber of Commerce PAC's endorsement for governor.

    July 14, 2025

    Source: ohio-chamber-object-storage-m0uzx.sevalla.storage

  • Received the Ohio Republican Party's endorsement for governor, voted by its state central committee a year before the primary.

    May 9, 2025

    Source: spectrumnews1.com

  • Received U.S. Sen. Bernie Moreno's endorsement for governor of Ohio.

    March 23, 2025

    Source: foxnews.com

  • Received President Donald Trump's endorsement for governor of Ohio.

    February 24, 2025

    Source: apnews.com

  • Posted on social media, during a Republican debate over H-1B skilled-worker visas, that American work culture had "venerated mediocrity over excellence."

    January 21, 2025

    Source: yahoo.com

  • Bought a 7.7% stake in BuzzFeed and wrote to its board urging it to add three new directors and make heavy cost cuts.

    May 28, 2024

    Source: thewrap.com

  • Endorsed Donald Trump for president after ending his own campaign and subsequently appeared at campaign events on Trump's behalf.

    January 15, 2024

    Source: apnews.com

  • Ramaswamy stepped down from Roivant Sciences' board of directors.

    February 21, 2023

    Source: sec.gov

  • Stepped down as Roivant Sciences' chief executive to become chairman of its board, citing his growing public engagement. Chief financial officer Matt Gline took over as CEO.

    January 25, 2021

    Source: biospace.com

  • As Roivant Sciences' founder and chief executive, agreed to a deal in which Sumitomo Dainippon Pharma paid Roivant $3 billion up front for stakes in its drug companies and an option on six more.

    November 1, 2019

    Source: biospace.com

  • Led Roivant's Axovant subsidiary when its lead Alzheimer's drug, intepirdine, failed both primary efficacy endpoints in a Phase 3 trial after the company had spent much of its IPO proceeds developing it.

    September 26, 2017

    Source: sec.gov

  • Led Axovant Sciences as chief executive through an initial public offering that sold 24.15 million shares at $15 each and generated about $334.5 million in net proceeds.

    June 16, 2015

    Source: sec.gov

Past race Vivek Ramaswamy ran in: